Experimental drug aims to restore platelets in Heparin-Triggered disorder

NCT ID NCT05785819

Terminated Disease control Sponsor: Veralox Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called VLX-1005 in people with a rare condition where the blood thinner heparin causes a dangerous drop in platelets (cells that help blood clot). Participants received either VLX-1005 or a placebo alongside standard care. The goal was to see if the drug could help platelet levels recover faster and prevent complications like blood clots or stroke. The study was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPARIN-INDUCED THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenia heparin-induced thrombocytopenia Purpura, Thrombocytopenic, Idiopathic thrombocytopenia thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPARIN-INDUCED THROMBOCYTOPENIA THROMBOCYTOPENIA, IMMUNE

Contacts and locations

Locations

Carilion Medical Center

Roanoke, Virginia, 24014, United States
Duke University

Durham, North Carolina, 27710, United States
Georgetown University

Washington D.C., District of Columbia, 20007, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
MedStar Washington Hospital Center

Washington D.C., District of Columbia, 20010, United States
Oregon Health and Science University

Portland, Oregon, 97239, United States
Stanford University

Stanford, California, 94305, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
University of Colorado

Aurora, Colorado, 80045, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Washington

Seattle, Washington, 98195, United States
Universiy of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Versiti at Froedtert Hospital

Milwaukee, Wisconsin, 53226, United States
Yale University

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.